Benzodiazepine

Summary

Benzodiazepine (CHEMBL4297264) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including anxiety.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 8
• Chemistry: 144.17 Da · C9H8N2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297264
Name	Benzodiazepine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	134664
Molecular formula	C9H8N2
Molecular weight	144.17
InChIKey	SVUOLADPCWQTTE-UHFFFAOYSA-N

SMILES: C1=CC=C2C(=C1)C=CC=NN2

IUPAC name: 1H-1,2-benzodiazepine

Also known as: Benzodiazepine, BENZODIAZEPINE

Patent coverage: 29,084 distinct patent families (97,152 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
anxiety	3	MONDO:0011918	EFO:0005230

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
Not specified	3
PHASE4	2
PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01050478	PHASE4	COMPLETED	IMPACT: A Study to Explore the Efficacy and Safety of Paliperidone ER in Patients With Acute Agitation
NCT02119806	PHASE4	WITHDRAWN	Decreasing the Incidence of Delirium After Cardiac Surgery
NCT01391962	PHASE2	COMPLETED	Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
NCT04299490	PHASE2	COMPLETED	Effects of Experimental Sleep Disturbances on Receptor Function of Study Drug
NCT06745297	PHASE1	RECRUITING	A Study in Healthy Men to Test How Well Different Doses of BI 3776528 Are Tolerated
NCT02775864	Not specified	COMPLETED	Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia
NCT04622995	Not specified	COMPLETED	Benzodiazepines in Opiate Replacement Therapy
NCT04856436	Not specified	COMPLETED	Maternal and Neonatal Outcomes Following Exposure to Benzodiazepines During Pregnancy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).